發(fā)布時間：2018-03-20 12:13

  本文選題：腫瘤異常蛋白　切入點：腦膠質(zhì)瘤　出處：《山西醫(yī)科大學》2017年碩士論文　論文類型：學位論文

【摘要】：目的:探討腫瘤異常蛋白(TAP)在腦膠質(zhì)瘤患者中的表達情況及其臨床應(yīng)用價值,為腦膠質(zhì)瘤的手術(shù)療效評估方面提供更多信息。方法:根據(jù)納入和排除標準,經(jīng)患者知情同意以及我院醫(yī)學倫理委員會批準,選取我院2015年10月至2016年12月神經(jīng)外科腦膠質(zhì)瘤住院患者病例及同期門診體檢健康人群作為研究對象,將其分為腦膠質(zhì)瘤組55例和體檢健康組120例。其中,腦膠質(zhì)瘤組經(jīng)術(shù)后病理確診并分級后再細分為膠質(zhì)瘤Ⅰ~Ⅱ級組19例和膠質(zhì)瘤Ⅲ~Ⅳ級組36例。分別檢測各組研究對象TAP的表達水平。腦膠質(zhì)瘤組患者術(shù)后1~2周內(nèi)均再次行TAP檢測,計算TAP在腦膠質(zhì)瘤中的陽性+臨界表達率及治療后的轉(zhuǎn)陰率,分析TAP的表達情況與腦膠質(zhì)瘤之間的關(guān)系。結(jié)果:(1)腦膠質(zhì)瘤組TAP陽性+臨界表達率為58.18%,明顯高于體檢健康組的4.17%,兩組間TAP陽性+臨界表達率比較差異有統(tǒng)計學意義(χ2=66.00,P0.05);(2)膠質(zhì)瘤Ⅰ~Ⅱ級組TAP陽性+臨界表達率為63.16%,雖高于膠質(zhì)瘤Ⅲ~Ⅳ級組的55.56%,但兩組間TAP陽性+臨界表達率比較差異無統(tǒng)計學意義(χ2=0.30,P0.05);(3)腦膠質(zhì)瘤組術(shù)后TAP轉(zhuǎn)陰率為71.88%。其中,膠質(zhì)瘤Ⅰ~Ⅱ級組轉(zhuǎn)陰率為75.00%,膠質(zhì)瘤Ⅲ~Ⅳ級組轉(zhuǎn)陰率為70.00%。結(jié)論:(1)TAP在腦膠質(zhì)瘤患者中的陽性+臨界表達率明顯高于健康人群,說明TAP的表達情況與腦膠質(zhì)瘤的發(fā)生有一定程度的相關(guān)性,但不足以用于腦膠質(zhì)瘤的診斷;(2)腦膠質(zhì)瘤的惡性程度與TAP的表達無明確相關(guān)性;(3)腦膠質(zhì)瘤術(shù)后TAP轉(zhuǎn)陰率較高,提示腦膠質(zhì)瘤在術(shù)前TAP檢測結(jié)果為陽性或臨界表達時,于術(shù)后再次檢測TAP可能會為其手術(shù)治療效果的優(yōu)劣提供參考,從而可能作為腦膠質(zhì)瘤手術(shù)療效評估的輔助檢測指標,進而為膠質(zhì)瘤的下一步治療提供有益參考。
[Abstract]:Objective: to investigate the expression of tumor abnormal protein (TAP) in patients with glioma and its clinical value, and to provide more information for the evaluation of surgical efficacy of glioma. Methods: according to the criteria of inclusion and exclusion, With the informed consent of the patient and the approval of the Medical Ethics Committee of our hospital, the inpatients with neurosurgical glioma from October 2015 to December 2016 and the healthy outpatient physical examination group were selected as the study subjects. It was divided into brain glioma group (55 cases) and physical examination group (120 cases). 19 cases of glioma 鈪，

本文編號：1639041